Pure Global AI
NCT05838703Withdrawn

Tiotropium Handihaler vs. Tiotropium Respimat in COPD

Comparing the Acute Effects of Tiotropium Handihaler With Tiotropium Respimat on the Ventilation Distribution in COPD Patients
Duke UniversityPhase 2ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Chronic Obstructive Pulmonary Disease (COPD)
Drug/Device/Intervention
tiotropium bromide inhalation powder (Spiriva HandiHaler)
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Duke University
Timeline & enrollment
Phase
Phase 2
Start date
May 01, 2023
End date
May 01, 2024
Enrollment
0 participants
Primary outcome

Assess the change in ventilation distribution parameters by 129Xe MRI in patient while taking Spiriva HandiHaler,Assess the change in ventilation distribution parameters by 129Xe MRI in patient while taking patient while taking Spiriva Respimat,Assess the changes in Pre- and Post-Spirometry procedure while on Spiriva HandiHaler,Assess the changes in Pre- and Post-Spirometry procedure while on Spiriva HandiHaler,Assess the changes in Pre- and Post-Spirometry procedure while on Spiriva HandiHaler,Assess the changes in Pre- and Post-Spirometry procedure while on Spiriva HandiHaler,Assess the changes in Pre- and Post-Spirometry procedure while on Spiriva Respimat,Assess the changes in Pre- and Post-Spirometry procedure while on Spiriva Respimat,Assess the changes in Pre- and Post-Spirometry procedure while on Spiriva Respimat,Assess the changes in Pre- and Post-Spirometry procedure while on Spiriva Respimat

Summary

The purpose of this study is to determine if tiotropium Respimat will result in better
 ventilation distribution of the lung in COPD participants quantified by hyperpolarized XeMRI.
 This study is designed to simulate the real-life clinical setting where patients receive
 one-time instruction on the inhaler use.

ICD-10 classifications
Other chronic obstructive pulmonary diseaseChronic obstructive pulmonary disease, unspecifiedOther specified chronic obstructive pulmonary diseaseChronic obstructive pulmonary disease with acute exacerbation, unspecifiedChronic obstructive pulmonary disease with acute lower respiratory infection
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05838703
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05838703 through Pure Global AI's free database. This Phase 2 trial is sponsored by Duke University and is currently Withdrawn. The study focuses on Chronic Obstructive Pulmonary Disease (COPD). Target enrollment is 0 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.